Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective.
Prostaglandin E concentrations were measured in a patiet with breast carcinoma, hypercalcemia, undetectable parathyroid hormone (PTH) and no evidence of bone metastases. Catheterization of the drainage bed of her tumor documented production of E series prostaglandins. Treatment with the largest recommended doses of indomethacin for 10 days failed to lower her plasma prostaglandin E (PGE) concentrations or to correct the hypercalcemia, but it normalized urinary excretion of PGE. Subsequent chemotherapy reduced prostaglandin concentrations toward normal values concomitant with a reduction of clinically estimated tumor burden. During this period of time, serum calcium concentrations had no consistent relationship to the plasma PGE levels. We suggest that PGE merely reflected the tumor burden of this patient and did not directly contribute to the genesis of her hypercalcemia. The pertinent literature relating PGE and hypercalcemia is reviewed.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood* / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D011458:Prostaglandins E / Q000097:blood*
D000970:Antineoplastic Agents; D010281:Parathyroid Hormone; D011458:Prostaglandins E